Cml

[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Etiology ,[object Object],[object Object]

Epidemiology ,[object Object],[object Object]

Pathogenesis ,[object Object],[object Object],[object Object],[object Object],[object Object]

Pathogenesis ,[object Object],[object Object],[object Object],[object Object]

Translocation t(9;22)(q34;q11)

Philadelphia Chromosome ,[object Object],[object Object]

The bcr/abl fusion protein ,[object Object],[object Object],[object Object],[object Object]

Clinical features ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Laboratory features ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Laboratory features (2) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Diagnosis ,[object Object],[object Object]

Accelerated phase of CML ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Blast phase (blast crisis) of CML ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Differential diagnosis ,[object Object],[object Object],[object Object],[object Object],[object Object]

Prognostic factors ,[object Object],[object Object],[object Object],[object Object]

Treatment ,[object Object],[object Object],[object Object],[object Object]

Treatment Algorithm for treating CML DIAGNOSIS Imatinib for all Response to imatinib ‘ Failed” response to imatinib Continue Consider for other TKI or SCT

Treatment ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Tr ea tment Imatinib mesylate (Gleevec) ,[object Object],[object Object],[object Object],[object Object]

Response evaluation No response loss Anytime ‡ MMolR 18 Months CCgR 12 Months ‡ PCgR 6 Months CHR 3 Months Optimal response: Time:

Criteria of cytogenetic response >95 lack of response 36-95 minor 1-35 maior 0 complete % of Ph in bone marrow Cytogenetic response

Criteria of molecular response Maior molecular response: ≥ 3-log reduction of BCR/ABL transcript in RQ-PCR Complete molecular response: BCR/ABL transcript undetectable in PCR

Aditional T reatment ,[object Object],[object Object],[object Object],[object Object]

Treatment of patients with blast crisis ( AML phenotype ) ,[object Object],[object Object],[object Object]

Treatment of patients with blast crisis ( ALL phenotype ) ,[object Object],[object Object],[object Object],[object Object]

Cml

Recomendados

Recomendados

Mais conteúdo relacionado

Mais procurados

Mais procurados (20)

Destaque

Destaque (20)

Semelhante a Cml

Semelhante a Cml (20)

Mais de Jasmine John

Mais de Jasmine John (20)

Último

Último (20)

Cml